|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500095514 |
|
最近更新日期: Date of Last Refreshed on: |
2025-01-08 11:02:22 |
|
注册时间: Date of Registration: |
2025-01-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
一项对比含伏诺拉生四联方案与经典四联方案根除幽门螺旋杆菌的疗效及安全性的回顾性、多中心、观察性临床研究 |
|
Public title: |
A retrospective, multicenter, observational clinical study comparing the efficacy and safety of helicobacter pylori eradication with vonorazone quadruple regimen versus classic quadruple regimen |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
一项对比含伏诺拉生四联方案与经典四联方案根除幽门螺旋杆菌的疗效及安全性的回顾性、多中心、观察性临床研究 |
|
Scientific title: |
A retrospective, multicenter, observational clinical study comparing the efficacy and safety of helicobacter pylori eradication with vonorazone quadruple regimen versus classic quadruple regimen |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
林鸿 |
研究负责人: |
黄雪平 |
|
Applicant: |
Lin Hong |
Study leader: |
Huang Xueping |
|
申请注册联系人电话: Applicant telephone: |
+86 180 5910 0729 |
研究负责人电话:
Study leader's |
+86 157 5081 9302 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
312046284@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
491589958@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省福州市鼓楼区东街134号 |
研究负责人通讯地址: |
福建省福州市鼓楼区东街134号 |
|
Applicant address: |
134 Street East, Gulou District, Fuzhou, Fujian |
Study leader's address: |
134 Street East, Gulou District, Fuzhou, Fujian |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
福建省立医院 |
||
|
Applicant's institution: |
Fujian Provincial Hospital |
||
|
研究负责人所在单位: |
福建省立医院 |
||
|
Affiliation of the Leader: |
Fujian Provincial Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审科研第(K2024-11-012)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
福建省立医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Fujian Provincial Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-11-25 00:00:00 | ||
|
伦理委员会联系人: |
练发杨 |
||
|
Contact Name of the ethic committee: |
Fayang Lian |
||
|
伦理委员会联系地址: |
福建省福州市鼓楼区东街134号 |
||
|
Contact Address of the ethic committee: |
134 Street East, Gulou District, Fuzhou, Fujian |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 136 4508 9026 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
福建省立医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Fujian Provincial Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省福州市鼓楼区东街134号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
134 Street East, Gulou District, Fuzhou, Fujian |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
福建省科技创新联合基金 ( 2023Y9296) |
||||||||||||||||||||||
|
Source(s) of funding: |
the Joint Funds for the Innovation of Science and Technology, Fujian province (Grant no. 2023Y9296) |
||||||||||||||||||||||
|
研究疾病: |
幽门螺杆菌感染 |
||||||||||||||||||||||
|
Target disease: |
Helicobacter pylori infection |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
通过低剂量伏诺拉生四联疗法对比传统含艾司奥美拉唑四联疗法根除幽门螺旋杆菌的真实世界、多中心、观察性临床研究,评估该方案的安全性和有效性,为Hp感染患者提供更加安全有效的根除方案。 |
||||||||||||||||||||||
|
Objectives of Study: |
The safety and efficacy of this regimen were evaluated through a real-world, multicenter,observational clinical study of the eradication of Helicobacter pylori with low-dose vonorasen quadruple therapy, and a safer and more effective eradication regimen for patients with Hp infection. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
纳入标准: 1.年龄在 18 至 70 岁之间。 2. 治疗前 4 周内未使用抗生素、铋剂或其他抗菌剂;治疗前 2 周内未使用 P-CAB、PPI、H2 受体拮抗剂或其他抑酸药物。 3.经 13C 或 14C 尿素呼气试验或快速尿素酶试验诊断为幽门螺杆菌阳性。 4.知情并同意参加本研究的患者,有完整的病历和随访数据。 |
||||||||||||||||||||||
|
Inclusion criteria |
Inclusion Criteria: 1.Age between 18 and 70 years. 2. No use of antibiotics, bismuth, or other antimicrobial agents within 4 weeks before treatment; no use of P-CAB, PPI, H2 receptor antagonists, or other acid-suppressing drugs within 2 weeks before treatment. 3.Diagnosed as H.pylori positive by 13C or 14C urea breath test or rapid urease test. 4.Patients who are informed and agree to participate in this study, with complete medical records and follow-up data. |
||||||||||||||||||||||
|
排除标准: |
1. 心、肺、肾、肝及血液系统等严重原发疾病者,免疫力低下者。 2. 存在药物过敏禁忌证者。 3. 存在精神疾病、沟通障碍者。 4. 妊娠期、哺乳期者。 5. 合并有消化道肿瘤、消化道出血等器质性病变。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with serious primary diseases of the heart, lung, kidney, liver and blood system, or immunocompromised. 2. Patients with drug allergy contraindications. 3. Those with mental illness and communication disorders. 4. Pregnant and lactating women. 5. Complicated with organic lesions such as gastrointestinal tumors and gastrointestinal bleeding. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-11-26 00:00:00至 To 2025-03-09 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-01-09 00:00:00 至 To 2025-02-09 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2025.03论文数据中公布 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The data in the paper is published in 2025.03 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |